Monday, June 25, 2018 12:00:04 PM
http://www.rmsmedicalproducts.com/news/ceo-andy-sealfon-discusses-rms-company-updates-exciting-news/
A couple of things stuck out. Andy talked about REPR entering the neuromodulation market, which deals with how the body handles rejection. He described it as a huge market, a game changer similar to penicillin(paraphrasing Andy's words). Traditionally the neuromodulation drugs were administered via IV because of flow requirements. Previously, in home infusion devices, the needle size and flow restriction precluded their use in high flow applications. Simply put, you need the flow but do not want a large needle. No longer the case due to a new REPR patent pending needle design
During the podcast Andy referred to a new administration set, with a patent pending needle design that allowed a higher flow rate. This is huge!! This is a game changer because it will give REPR a unique competitive advantage for high flow applications. Additionally, the new needle design, enhances REPR value as a takeover candidate. It is better to own a technology and prevent the competition from having it.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM